Interferon-α Inhibits NET Formation in Neutrophils Derived from Patients with Myeloproliferative Neoplasms in a Neutrophil Sub-Population-Specific Manner
2024

Interferon-α and Neutrophil NET Formation in Myeloproliferative Neoplasms

Sample size: 39 publication 10 minutes Evidence: moderate

Author Information

Author(s): Partouche Shirly, Goldberg Idan, Halperin Erez, Atamna Bahaa, Shacham-Abulafia Adi, Shapira Saar, Samara Aladin, Gover-Proaktor Ayala, Leader Avi, Spectre Galia, Raanani Pia, Granot Galit, Wolach Ofir, Awasthi Deepika

Primary Institution: Felsenstein Medical Research Center, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel

Hypothesis

Does interferon-α inhibit NET formation in neutrophils derived from patients with myeloproliferative neoplasms?

Conclusion

Interferon-α significantly inhibits NET formation in high-density neutrophils from patients with myeloproliferative neoplasms.

Supporting Evidence

  • High-density neutrophils drive excess NET formation in patients with myeloproliferative neoplasms.
  • Interferon-α treatment led to a significant reduction in neutrophil elastase activity in patient samples.
  • Neutrophil elastase activity was more prominently reduced in polycythemia vera patients compared to essential thrombocytosis patients.
  • Healthy controls did not exhibit significant changes in NET formation after interferon-α treatment.

Takeaway

This study found that a type of medicine called interferon-α can help stop certain white blood cells from making too many sticky nets that can cause problems in patients with blood disorders.

Methodology

The study analyzed neutrophil sub-population dynamics and NET formation in patients with myeloproliferative neoplasms, comparing results with healthy controls.

Potential Biases

Gender imbalance in the Density analysis group may reflect the limited number of patients.

Limitations

The study may be affected by factors such as co-morbidities, medications, and neutrophil isolation procedures.

Participant Demographics

Median age of participants was 51 years, with a mix of males and females; 48% had polycythemia vera.

Statistical Information

P-Value

p ≤ 0.006

Statistical Significance

p ≤ 0.006

Digital Object Identifier (DOI)

10.3390/ijms252413473

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication